PDF(Pubmed)
Abstract：
Relapse remains a major cause of treatment failure following allogeneic stem cell transplantation (allo-SCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We retrospectively investigated low-dose decitabine and venetoclax (DEC/VEN) as post-transplant maintenance in 26 older patients with AML and MDS. The cumulative incidence of day 100 gIII-IV acute graft versus host disease (GVHD) and 1-year moderate-severe chronic GVHD was 5% and 26%, respectively. One patient relapsed 14 m after transplant. The 1-year non-relapse mortality and survival were 11% and 84%, respectively. DEC/VEN is a safe and potentially effective strategy to reduce the risk of post-transplant relapse.
摘要：
急性髓性白血病（AML）和骨髓增生异常综合征（MDS）患者的异基因干细胞移植（allo-SCT）后复发仍然是治疗失败的主要原因。我们回顾性研究了26例老年AML和MDS患者的低剂量地西他滨和维奈托克（DEC/VEN）作为移植后维持治疗。第100天gIII-IV急性移植物抗宿主病（GVHD）和1年中重度慢性GVHD的累积发病率为5％和26％，分别。一名患者在移植后14m复发。1年非复发死亡率和生存率分别为11%和84%。分别。DEC/VEN是降低移植后复发风险的安全且潜在有效的策略。
